Company Description
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.
It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB.
AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Eric Easom |
Contact Details
Address: 1300 El Camino Real, Suite 100 Menlo Park, California 94025 United States | |
| Phone | 650 331 9090 |
| Website | an2therapeutics.com |
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| Employer ID | 82-0606654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President and Chairman of the Board |
| Joseph S. Zakrzewski | Co-Founder and Independent Chairman of the Board |
| Lucy O. Day CPA | Chief Financial Officer, and Principal Financial Officer |
| Joshua M. Eizen J.D. | Chief Legal Officer, Chief Operating Officer and Corporate Secretary |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder and Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior Vice President of Research Fellow and Head of Biology |
| Sarah Williams | Vice President of Controller and Principal Accounting Officer |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Vince Hernandez | Senior Vice President of Research and Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 17, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 16, 2026 | SCHEDULE 13G | Filing |
| Mar 13, 2026 | SCHEDULE 13G | Filing |
| Mar 13, 2026 | SCHEDULE 13G | Filing |
| Mar 10, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |